moatshark My

All holdings

Neurocrine Biosciences

NBIX

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$941m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$168.53
+27.9% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-16.3%Q3 ’24
+18.5%Q4 ’24
-19.0%Q1 ’25
+13.6%Q2 ’25
+11.7%Q3 ’25
+1.0%Q4 ’25
-7.1%Q1 ’26
+27.9%Q2 ’26
Q3 ’24: -16.3%; Q4 ’24: +18.5%; Q1 ’25: -19.0%; Q2 ’25: +13.6%; Q3 ’25: +11.7%; Q4 ’25: +1.0%; Q1 ’26: -7.1%; Q2 ’26: +27.9%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

1Q4 ’23
1Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 1; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Neurocrine Biosciences.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Neurocrine Biosciences
Dodge & Cox0.5%$941m$941mAdded +2.3%12 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Neurocrine Biosciences
Bought or soldFiling
14 Sep 2026Abernethy MattChief Financial Officer▼ Sold2,311$157.20$363kForm 4
14 Sep 2026Boyer David W.Chief Corp. Affairs Officer▼ Sold826$157.45$130kForm 4
9 Sep 2026Benevich EricChief Commercial Officer▼ Sold2,154$154.61$333kForm 4
28 Jul 2026Norwalk Leslie VDirector▼ Sold1,250$182.01$228kForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
102m at 22 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$2.9m2013
$19.8m2015
$162m2017
$788m2019
$1.1bn2021
$1.9bn2023
$2.9bn2025
2013: $2.9m; 2014: $0k; 2015: $19.8m; 2016: $15.0m; 2017: $162m; 2018: $451m; 2019: $788m; 2020: $1.0bn; 2021: $1.1bn; 2022: $1.5bn; 2023: $1.9bn; 2024: $2.4bn; 2025: $2.9bn
Neurocrine Biosciences revenue and net income by year
YearRevenueNet income
2025$2.9bn$479m
2024$2.4bn$341m
2023$1.9bn$250m
2022$1.5bn$155m
2021$1.1bn$89.6m
2020$1.0bn$407m
2019$788m$37.0m
2018$451m$21.1m
2017$162m−$143m
2016$15.0m−$141m
2015$19.8m−$88.9m
2014$0k−$60.5m
2013$2.9m−$46.1m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Neurocrine Biosciences, from their latest N-PORT filings.

Funds holding Neurocrine Biosciences
Dodge & Cox Global Stock FundDodge & Cox0.2%$25.5m30 Jun 2026